{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:47:41Z","timestamp":1791823661373,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1-0777"],"award-info":[{"award-number":["W81XWH-19-1-0777"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0267"],"award-info":[{"award-number":["W81XWH-21-1-0267"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA282906"],"award-info":[{"award-number":["R01 CA282906"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA299202"],"award-info":[{"award-number":["R01 CA299202"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA156734"],"award-info":[{"award-number":["U54 CA156734"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    FOXA1 is a critical transcription factor in prostate cancer (PCa) progression, functioning as a pioneer factor for the androgen receptor (AR). Its expression is elevated in advanced stages of PCa and plays a central role in oncogenic reprogramming. Recurrent coding mutations in the forkhead DNA-binding domain (FKHD) of FOXA1 become increasingly prevalent in drug-resistant metastatic PCa, particularly clustering in the Wing2 region of FKHD. While recent studies demonstrated that these mutations promote PCa progression, the downstream targets of FKHD mutants remain poorly understood. In this study, we employed three analytical approaches to elucidate these targets: (i) traditional transcriptomic analyses, (ii) chromatin structure\u2013based super-enhancer (SE) profiling, and (iii) immune deconvolution. We identified HPSE, an enzyme that degrades heparan sulfate, as a druggable target activated by FKHD mutants both in vitro and in vivo. SE profiling further revealed that FKHD mutants can reprogram the SE landscape, with FOXP1 emerging as a consistently SE-driven and upregulated gene across multiple FOXA1 mutants. Additionally, FOXA1 mutations were associated with immune suppression in PCa patient samples, and\n                    <jats:italic>B2M<\/jats:italic>\n                    , a key gene in antigen processing and presentation, was notably downregulated in FKHD-mutant tumors. Together, our findings provide distinct insights into how FOXA1 FKHD mutations drive PCa progression and highlight potential therapeutic targets in tumors harboring these mutations.\n                  <\/jats:p>","DOI":"10.1038\/s42003-026-10523-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:55:15Z","timestamp":1782233715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1487-5002","authenticated-orcid":false,"given":"Yuxin","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruogyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-2586","authenticated-orcid":false,"given":"Changmeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-8801","authenticated-orcid":false,"given":"Shuai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"10523_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fendo.2012.00068","volume":"3","author":"JL Robinson","year":"2012","unstructured":"Robinson, J. L. & Carroll, J. S. FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front Endocrinol. (Lausanne) 3, 68 (2012).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10523_CR2","doi-asserted-by":"publisher","unstructured":"Hwang, J. et al. Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3471 (2025).","DOI":"10.1158\/1078-0432.CCR-24-3471"},{"key":"10523_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","volume":"571","author":"A Parolia","year":"2019","unstructured":"Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413\u2013418 (2019).","journal-title":"Nature"},{"key":"10523_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","volume":"571","author":"EJ Adams","year":"2019","unstructured":"Adams, E. J. et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571, 408\u2013412 (2019).","journal-title":"Nature"},{"key":"10523_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research, N.","year":"2015","unstructured":"Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"10523_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41422-019-0204-1","volume":"29","author":"B Xu","year":"2019","unstructured":"Xu, B. et al. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression. Cell Res. 29, 773\u2013775 (2019).","journal-title":"Cell Res."},{"key":"10523_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41422-019-0203-2","volume":"29","author":"S Gao","year":"2019","unstructured":"Gao, S. et al. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 29, 770\u2013772 (2019).","journal-title":"Cell Res"},{"key":"10523_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57854-w","volume":"14","author":"KJ Tam","year":"2024","unstructured":"Tam, K. J. et al. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. Sci. Rep. 14, 7082 (2024).","journal-title":"Sci. Rep."},{"key":"10523_CR9","doi-asserted-by":"publisher","unstructured":"Eyunni, S. et al. Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity. Science, eadv2367 https:\/\/doi.org\/10.1126\/science.adv2367 (2025).","DOI":"10.1126\/science.adv2367"},{"key":"10523_CR10","doi-asserted-by":"publisher","first-page":"10181","DOI":"10.1523\/JNEUROSCI.0541-16.2016","volume":"36","author":"AR Lee","year":"2016","unstructured":"Lee, A. R. et al. Putative cell adhesion membrane protein vstm5 regulates neuronal morphology and migration in the central nervous system. J. Neurosci. 36, 10181\u201310197 (2016).","journal-title":"J. Neurosci."},{"key":"10523_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60290-1","volume":"10","author":"X Ding","year":"2020","unstructured":"Ding, X. et al. Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction. Sci. Rep. 10, 3417 (2020).","journal-title":"Sci. Rep."},{"key":"10523_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02624-1","volume":"18","author":"KM Jayatilleke","year":"2020","unstructured":"Jayatilleke, K. M. & Hulett, M. D. Heparanase and the hallmarks of cancer. J. Transl. Med. 18, 453 (2020).","journal-title":"J. Transl. Med"},{"key":"10523_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ol.2024.14217","volume":"27","author":"X Li","year":"2024","unstructured":"Li, X. et al. Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL\u20111. Oncol. Lett. 27, 83 (2024).","journal-title":"Oncol. Lett."},{"key":"10523_CR14","doi-asserted-by":"publisher","unstructured":"Li, M. et al. LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2433 (2023).","DOI":"10.1158\/0008-5472.CAN-22-2433"},{"key":"10523_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","volume":"52","author":"MM Pomerantz","year":"2020","unstructured":"Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet 52, 790\u2013799 (2020).","journal-title":"Nat. Genet"},{"key":"10523_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327 (2022).","journal-title":"Neoplasia"},{"key":"10523_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","volume":"2120","author":"J Racle","year":"2020","unstructured":"Racle, J. & Gfeller, D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol. Biol. 2120, 233\u2013248 (2020).","journal-title":"Methods Mol. Biol."},{"key":"10523_CR18","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"10523_CR19","doi-asserted-by":"publisher","unstructured":"He, Y. et al. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest 131 https:\/\/doi.org\/10.1172\/JCI147025 (2021).","DOI":"10.1172\/JCI147025"},{"key":"10523_CR20","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1038\/s41388-022-02423-6","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene 41, 4259\u20134270 (2022).","journal-title":"Oncogene"},{"key":"10523_CR21","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1007\/s11033-023-08251-5","volume":"50","author":"OAA Mohamed","year":"2023","unstructured":"Mohamed, O. A. A. et al. The role of hypoxia on prostate cancer progression and metastasis. Mol. Biol. Rep. 50, 3873\u20133884 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"10523_CR22","doi-asserted-by":"publisher","first-page":"33594","DOI":"10.1074\/jbc.M112.388298","volume":"287","author":"T Mitani","year":"2012","unstructured":"Mitani, T., Harada, N., Nakano, Y., Inui, H. & Yamaji, R. Coordinated action of hypoxia-inducible factor-1alpha and beta-catenin in androgen receptor signaling. J. Biol. Chem. 287, 33594\u201333606 (2012).","journal-title":"J. Biol. Chem."},{"key":"10523_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918419","volume":"12","author":"V Masola","year":"2022","unstructured":"Masola, V. et al. Heparanase regulates EMT and cancer stem cell properties in prostate tumors. Front Oncol. 12, 918419 (2022).","journal-title":"Front Oncol."},{"key":"10523_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.matbio.2019.11.004","volume":"88","author":"K Tripathi","year":"2020","unstructured":"Tripathi, K. et al. Heparanase promotes myeloma stemness and in vivo tumorigenesis. Matrix Biol. 88, 53\u201368 (2020).","journal-title":"Matrix Biol."},{"key":"10523_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203167119","volume":"119","author":"C de Boer","year":"2022","unstructured":"de Boer, C. et al. Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo. Proc. Natl. Acad. Sci. USA 119, e2203167119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10523_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/pros.24602","volume":"83","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer. Prostate 83, 1458\u20131469 (2023).","journal-title":"Prostate"},{"key":"10523_CR27","doi-asserted-by":"publisher","unstructured":"Park, S. H. et al. Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer. Sci. Adv. 7 https:\/\/doi.org\/10.1126\/sciadv.abe2261 (2021).","DOI":"10.1126\/sciadv.abe2261"},{"key":"10523_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","volume":"52","author":"S Gao","year":"2020","unstructured":"Gao, S. et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat. Genet 52, 1011\u20131017 (2020).","journal-title":"Nat. Genet"},{"key":"10523_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/cbin.10702","volume":"41","author":"S Oskay Halacli","year":"2017","unstructured":"Oskay Halacli, S. FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells. Cell Biol. Int 41, 102\u2013110 (2017).","journal-title":"Cell Biol. Int"},{"key":"10523_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2025.10.020","volume":"59","author":"JM Umhoefer","year":"2026","unstructured":"Umhoefer, J. M. et al. FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry. Immunity 59, 129\u2013144 e113 (2026).","journal-title":"Immunity"},{"key":"10523_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.11.066","volume":"39","author":"P De Silva","year":"2019","unstructured":"De Silva, P. et al. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine 39, 226\u2013238 (2019).","journal-title":"EBioMedicine"},{"key":"10523_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/leu.2015.299","volume":"30","author":"PJ Brown","year":"2016","unstructured":"Brown, P. J. et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30, 605\u2013616 (2016).","journal-title":"Leukemia"},{"key":"10523_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/83784","volume":"27","author":"ME Brunkow","year":"2001","unstructured":"Brunkow, M. E. et al. Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet 27, 68\u201373 (2001).","journal-title":"Nat. Genet"},{"key":"10523_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1207081","volume":"13","author":"S Jiang","year":"2023","unstructured":"Jiang, S. et al. Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types. Front Oncol. 13, 1207081 (2023).","journal-title":"Front Oncol."},{"key":"10523_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944194","volume":"12","author":"L Lu","year":"2022","unstructured":"Lu, L. et al. Overexpression of OAS1 is correlated with poor prognosis in pancreatic cancer. Front Oncol. 12, 944194 (2022).","journal-title":"Front Oncol."},{"key":"10523_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01058-x","volume":"28","author":"S Cui","year":"2023","unstructured":"Cui, S. et al. The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. Eur. J. Med. Res. 28, 90 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"10523_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm, G., Finotello, F. & List, M. Immunedeconv: An R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol. Biol. 2120, 223\u2013232 (2020).","journal-title":"Methods Mol. Biol."},{"key":"10523_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"10523_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10523-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:04:45Z","timestamp":1791821085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10523"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10523-2","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1326"}}